Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Pick a strategy above and run the backtest to see its simulated performance on ACRS.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
Shares of Aclaris Therapeutics are down 8.11% at $3.40. The company is worth $500.48M, number 3745 out of 3753 on our list.
The stock's 52-week band runs $1.74 to $6.60, and the latest print sits 48.5% under the top end of it. Holders are ahead 78.9% over twelve months, but down 40.5% across the last three months.
On the chart it has slipped under both the 50-day ($5.62) and 200-day ($4.46) moving averages; RSI is 22, which some call oversold, and the last 30 sessions moved at roughly 84% annualized volatility.
5 analysts follow the stock and the average call is "buy". The mean target, $12.00, sits 252.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3752 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
5 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ACRS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $12.00, 252.9% above today’s price, with a consensus rating of Buy.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -33.0% | Bearish |
| Price vs 50-day average | -39.5% | Bearish |
| Price vs 200-day average | -23.8% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 21.9 | Neutral |
| MACD (12,26,9) | -0.49 | Bearish |
| Bollinger band position | -13% | Neutral |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 8, 2026 8:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,752 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$3.40 is the latest print for ACRS, a move of -8.11% against yesterday's close of $3.70. Today's low and high so far: $3.32 and $3.62.
Equity value comes to $500.48M at the current price. By that measure it is number 3745 of the 3753 names in our coverage.
The year's floor is $1.74 and the ceiling $6.60. Shares are 48.5% away from that ceiling.
Our data shows no dividend paid by Aclaris Therapeutics over the trailing twelve months.
Of 5 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $12.00, with the most cautious at $10.00 and the most optimistic at $16.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ACRS.